Medindia

X

Apixaban Reduces the Incidence of Venous Thrombo Embolism (VTE)

by Dr. Trupti Shirole on  December 25, 2010 at 10:11 PM Clinical Trials News   - G J E 4
Benefits of the venous thrombo embolism (VTE) drug apixaban when compared to its leading rival Sanofi-aventi's enoxaparin have been published by the staff in clinical research jobs at Pfizer and Bristol-Myers Squibb (BMS). Apixaban has been developed as part of a global collaborative agreement signed by Pfizer and BMS in 2007.
 Apixaban Reduces the Incidence of Venous Thrombo Embolism (VTE)
Apixaban Reduces the Incidence of Venous Thrombo Embolism (VTE)
Advertisement

Apixaban, which is administered orally, outperformed enoxaparin in reducing the incidence of venous thrombo embolism (VTE) among patients undergoing elective total hip replacement surgery.

Advertisement
Lead investigator of the study, Dr Michael Rud Lassen of the Hoersholm Hospital in Copenhagen said, "This is encouraging, as the risk of bleeding is a key concern for orthopedic surgeons using oral anticoagulants." In August 2010, clinical data had been published that assessed the effectiveness of apixaban as compared to aspirin, in preventing strokes among atrial fibrillation patients.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All